Hôspital Saint-Louis expands partnership with SOPHiA GENETICS
Hospital Saint-Louis in Paris has expanded its partnership with Swiss-based software program firm Sophia Genetics.
By this partnership, the hospital will leverage the SOPHiA DDM platform to advance its analysis into myeloid illnesses, particularly myeloproliferative neoplasms (MPNs).
The hospital's Mobile Biology Division, which focuses on in-depth medical analysis to supply complete look after MPN sufferers, goals to speed up analysis via the platform's streamlined workflows.
This cloud-native answer allows customized next-generation sequencing workflows, offering researchers with high-quality, reproducible information from present gene panels.
It claims to assist researchers perceive the exact characterization of the advanced mutational panorama related to myeloid neoplasms.
Hôpital Saint-Louis Molecular Diagnostics researcher Bruno Cassinat mentioned: “Whereas the healthcare suppliers and researchers in my division have many years of expertise with MPNs and are well-versed in delivering the very best high quality care to our sufferers, we welcome the assist of the revolutionary know-how that SOPHiA GENETICS affords.
Acquire entry to probably the most complete firm profiles available on the market, powered by GlobalData. Save hours of analysis. Acquire aggressive benefit.
Firm Profile – Free Pattern
Your obtain e mail will arrive shortly
We’ve got confidence within the distinctive high quality of our firm profiles. Nonetheless, we wish you to take advantage of useful determination for your corporation. That's why we give you a free pattern that you would be able to obtain by submitting the shape beneath.
By GlobalData
“The SOPHiA DDM platform has been an important device in supporting us in streamlining our bioinformatics workflows, accelerating our analysis and making data-driven choices for our affected person inhabitants.”
The platform makes use of synthetic intelligence (AI) to effectively analyze and interpret advanced NGS information, serving to researchers shortly achieve streamlined insights to assist sufferers make data-backed suggestions.
SOPHiA GENETICS EMEA managing director Kevin Puylaert mentioned: “As we proceed to increase using data-driven medication world wide, we’re laser-focused on serving to hospitals and laboratories with their efforts to maintain tempo with rising worldwide suggestions and virtually fixed progress has been made in focused therapies for myeloid illnesses.
“The SOPHiA DDM platform is designed to make sure that our prospects not solely have entry to NGS workflows, but in addition have the instruments they should establish insights that can assist information investigations, speed up investigations and enhance will inform decision-making.”
Hôpital Saint-Louis has been a referral middle for greater than 50 years.
Final month, a regional and college hospital in France CHU de Nîmes expanded its collaboration with SOPHiA GENETICS to make use of the SOPHiA DDM platform for pharmacogenomic analysis.
